公开(公告)号：US11160783B2

公开(公告)日：2021-11-02

申请号：US15960259

申请日：2018-04-23

Applicant: Eisai R&D Management Co., LTD.

Inventor： Sergei Agoulnik ,  Bruce Decosta ,  Hong Du ,  Yimin Jiang ,  Xiang-Yi Li ,  Kenichi Nomoto ,  John (Yuan) Wang ,  Huiming Zhang

IPC: A61K31/365 ,  A61P35/00 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/422 ,  A61K31/4523 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/665 ,  A61K45/06

Abstract: The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): wherein R1-R3 are as defined herein, or pharmaceutically acceptable salts or esters thereof; and a pharmaceutically acceptable carrier.

公开(公告)号：US09695188B2

公开(公告)日：2017-07-04

申请号：US15059965

申请日：2016-03-03

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yongbo Hu ,  Huiming Zhang ,  Hiroyuki Chiba ,  Yuki Komatsu ,  Bryan M. Lewis

IPC: C07D321/00 ,  C07D493/22

CPC classification number: C07D493/22

Abstract: In general, the present invention features improved methods useful for the synthesis of analogs of halichondrin B, such as eribulin and pharmaceutically acceptable salts thereof (e.g., eribulin mesylate).

公开(公告)号：US20180353468A1

公开(公告)日：2018-12-13

申请号：US15960259

申请日：2018-04-23

Applicant: Eisai R&D Management Co., LTD.

Inventor： Sergei Agoulnik ,  Bruce Decosta ,  Hong Du ,  Yimin Jiang ,  Xiang-Yi Li ,  Kenichi Nomoto ,  John (Yuan) Wang ,  Huiming Zhang

IPC: A61K31/365 ,  A61K45/06 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/422 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/665 ,  A61K31/4523

CPC classification number: A61K31/365 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/422 ,  A61K31/4523 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/665 ,  A61K45/06

Abstract: The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): wherein R1-R3 are as defined herein, or pharmaceutically acceptable salts or esters thereof; and a pharmaceutically acceptable carrier.

公开(公告)号：US09303039B2

公开(公告)日：2016-04-05

申请号：US14562086

申请日：2014-12-05

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Huiming Zhang ,  Bryan M. Lewis

IPC: C07D321/00 ,  C07D493/22

CPC classification number: C07D493/22

Abstract: In general, the present invention features improved methods useful for the synthesis of analogs of halichondrin B, such as eribulin and pharmaceutically acceptable salts thereof (e.g., eribulin mesylate).

Abstract translation: 通常，本发明的特征在于可用于合成软骨素B类似物的改进方法，例如胡椒素及其药学上可接受的盐（例如，甲磺酸eribulin）。

公开(公告)号：US08937056B2

公开(公告)日：2015-01-20

申请号：US13794635

申请日：2013-03-11

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Sergei Agoulnik ,  Bruce Decosta ,  Hong Du ,  Yimin Jiang ,  Xiang-Yi Li ,  Kenichi Nomoto ,  John (Yuan) Wang ,  Huiming Zhang

IPC: A01N57/00 ,  A61K31/665 ,  A01N43/02 ,  A61K31/335 ,  A01N43/76 ,  A61K31/42 ,  A61K31/415 ,  A61K31/497 ,  A61K31/535 ,  A61K31/4178 ,  A61K31/365 ,  A61K31/422 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/496 ,  A61K31/4025 ,  A61K31/4523

CPC classification number: A61K31/365 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/422 ,  A61K31/4523 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/665 ,  A61K45/06

Abstract: The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): wherein R1-R3 are as defined herein, or pharmaceutically acceptable salts or esters thereof; and a pharmaceutically acceptable carrier.

Abstract translation: 本发明提供了用于治疗特定癌症的化合物，药物组合物和方法。 这样的组合物通常可以包含式（I）的化合物：其中R 1 -R 3如本文所定义，或其药学上可接受的盐或酯; 和药学上可接受的载体。

公开(公告)号：US10450324B2

公开(公告)日：2019-10-22

申请号：US16031629

申请日：2018-07-10

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Yongbo Hu ,  Huiming Zhang ,  Hiroyuki Chiba ,  Yuki Komatsu ,  Bryan M. Lewis

IPC: C07D493/22

Abstract: In general, the present invention features improved methods useful for the synthesis of analogs of halichondrin B, such as eribulin and pharmaceutically acceptable salts thereof (e.g., eribulin mesylate).

公开(公告)号：US20150182496A1

公开(公告)日：2015-07-02

申请号：US14595746

申请日：2015-01-13

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Sergei Agoulnik ,  Bruce Decosta ,  Hong Du ,  Yimin Jiang ,  Xiang-Yi Li ,  Kenichi Nomoto ,  John (Yuan) Wang ,  Huiming Zhang

IPC: A61K31/365 ,  A61K31/496 ,  A61K45/06 ,  A61K31/4025 ,  A61K31/422 ,  A61K31/665 ,  A61K31/4178 ,  A61K31/5377

CPC classification number: A61K31/365 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/422 ,  A61K31/4523 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/665 ,  A61K45/06

Abstract: The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): wherein R1-R3 are as defined herein, or pharmaceutically acceptable salts or esters thereof; and a pharmaceutically acceptable carrier.

Abstract translation: 本发明提供了用于治疗特定癌症的化合物，药物组合物和方法。 这样的组合物通常可以包含式（I）的化合物：其中R 1 -R 3如本文所定义，或其药学上可接受的盐或酯; 和药学上可接受的载体。

公开(公告)号：US08962858B2

公开(公告)日：2015-02-24

申请号：US14316321

申请日：2014-06-26

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Branko Mitasev ,  Dae-Shik Kim ,  Huiming Zhang ,  Christopher N. Farthing

IPC: C07D498/04 ,  C07D307/22 ,  C07D513/04

CPC classification number: C07D307/22 ,  C07D498/04 ,  C07D513/04

Abstract: Provided are compounds and methods useful for the preparation of compounds useful as inhibitors of beta-site amyloid precursor protein (APP)-cleaving enzyme.

Abstract translation: 提供了可用于制备可用作β-位淀粉样蛋白前体蛋白（APP）消除酶抑制剂的化合物的化合物和方法。

公开(公告)号：US20130197244A1

公开(公告)日：2013-08-01

申请号：US13795308

申请日：2013-03-12

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Branko Mitasev ,  Dae-Shik Kim ,  Huiming Zhang ,  Matthew J. Schnaderbeck ,  Christopher N. Farthing

IPC: C07D307/22

CPC classification number: C07D307/22 ,  C07D498/04 ,  C07D513/04

Abstract: Provided are compounds and methods useful for the preparation of compounds useful as inhibitors of beta-site amyloid precursor protein (APP)-cleaving enzyme.

Abstract translation: 提供了可用于制备可用作β-位淀粉样蛋白前体蛋白（APP）消除酶抑制剂的化合物的化合物和方法。

公开(公告)号：US20140309429A1

公开(公告)日：2014-10-16

申请号：US14316321

申请日：2014-06-26

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Branko Mitasev ,  Dae-Shik Kim ,  Huiming Zhang ,  Christopher N. Farthing

IPC: C07D498/04

CPC classification number: C07D307/22 ,  C07D498/04 ,  C07D513/04

Abstract: Provided are compounds and methods useful for the preparation of compounds useful as inhibitors of beta-site amyloid precursor protein (APP)-cleaving enzyme.

Abstract translation: 提供了可用于制备可用作β-位淀粉样蛋白前体蛋白（APP）消除酶抑制剂的化合物的化合物和方法。